Drug intelligence / Profile preview

AB-5000

Development stage: Preclinical
Lead developer: Arsenal Biosciences
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AB-5000 is an investigational T-lymphocyte cell therapy being developed for the treatment of solid tumors, primarily within the therapeutic area of neoplasms. The drug is in preclinical development and is part of a collaboration between Arsenal Biosciences and Bristol Myers Squibb. Its mechanism of action has not been explicitly disclosed, but as a T-cell therapy, it likely involves engineering patient or donor T cells to recognize and attack cancer cells. The program appears to be one in a series (the "AB-5000 series") focused on solid tumor indications.

Beyond the preview

Go deeper on AB-5000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-5000.

Explore the full profile